SHIONOGI & CO., LTD.

Notification of Results of Share Repurchase

Through the Off-auction Own Share Repurchase Transaction (ToSTNeT-3) System

---

Osaka, Japan, November 8, 2016 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that it repurchased shares of its common stock today, pursuant to the announcement made on November 7, 2016, as described below.

1. Reason for share purchase

Shionogi will acquire own shares in order to increase shareholder return and capital efficiency by following a flexible capital policy, aligning with strong business progress in accordance with its medium-term business plan SGS2020, to maximize its enterprise value.

2. Details of repurchase

(1) Class of shares to be acquired — Common stock of the Company
(2) Total number of shares to be acquired — 5,469,300 shares
(1.68% of total outstanding shares [excluding treasury stock])
(3) Aggregate repurchased amount — 27,849,675,600 yen
(4) Date of repurchase — November 8, 2016
(5) Method of repurchase — Through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)

(Reference) Details pertaining to the share repurchase resolved at the meeting of the Board of Directors held on October 31, 2016.

(1) Class of shares to be acquired — Common stock of the Company
(2) Total number of shares to be acquired — 7,000,000 shares (maximum)
(2.15% of total outstanding shares [excluding treasury stock])
(3) Total amount of acquisition cost — 35 billion yen (maximum)
(4) Current states (November 8, 2016)
- Total number of shares to be acquired 5,469,300 shares
- Aggregate repurchased amount 27,849,675,600 yen

Forward-looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596